Rosen P J
Division of Hematology/Oncology, University of California, School of Medicine, Los Angeles.
Hematol Oncol Clin North Am. 1992 Dec;6(6):1315-28.
Bleeding problems in the cancer patient may result from the effects of the tumor on hemostatic mechanisms or from the treatment of the tumor by cytotoxic and other agents. Among the tumor-related bleeding problems are disseminated intravascular coagulation, primary fibrinolysis, thrombocytopenia, acquired platelet dysfunction, and circulating inhibitors or anticoagulants. Disseminated intravascular coagulation in most solid tumors is associated with hypercoagulability, whereas in acute promyelocytic leukemia bleeding is the most common presentation. Treatment-related bleeding disorders include the common problem of thrombocytopenia secondary to myelosuppressive chemotherapy as well as the interesting microangiopathic hemolytic anemia syndrome associated with mitomycin C and other agents.
癌症患者的出血问题可能源于肿瘤对止血机制的影响,或源于细胞毒性药物及其他药物对肿瘤的治疗。与肿瘤相关的出血问题包括弥散性血管内凝血、原发性纤溶、血小板减少、获得性血小板功能障碍以及循环抑制物或抗凝剂。大多数实体瘤中的弥散性血管内凝血与高凝状态有关,而在急性早幼粒细胞白血病中,出血是最常见的表现。与治疗相关的出血性疾病包括骨髓抑制性化疗继发的常见血小板减少问题,以及与丝裂霉素C和其他药物相关的有趣的微血管病性溶血性贫血综合征。